Biotech Values

[ghmm]

They target enoxaparin, which may be 2-3-4%, at most to their bottom line.

2% of TEVA > 100% of MNTA
3% of TEVA > 150% of MNTA
4% of TEVA > 200% of MNTA

I am long MNTA and hope Teva does not get a generic approved soon but respect what RockRat, genisi, Peter and others are trying to point out. If one also considers biologics and the market opportunity for generics there and I think people here agree it will require more technology then "unsophisticated drugs" why wouldn't Teva have spent at least 2-3-4% there.... which is a huge amount in Momenta's eyes .